Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine 257049 in the Sporozoite Challenge Model in Healthy Malaria-naive Adults

Next Previous
Trial Profile

Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine 257049 in the Sporozoite Challenge Model in Healthy Malaria-naive Adults

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 31 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GSK 257049 (Primary)
  • Indications Falciparum malaria
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline; GSK

Most Recent Events

  • 10 Feb 2018 Results of pooled analysis of this and other five phase II studies assessing relationship between HLA allele groups and RTS,S-mediated protection in controlled human malaria infections, published in the Vaccine.
  • 13 Jun 2016 Primary endpoint has been met. (Occurrence of P. falciparum parasitemia in the 0, 1, 2-month group), as per an article published in the Journal of Infectious Diseases.
  • 13 Jun 2016 Primary endpoint has been met. (Occurrence of Plasmodium falciparum parasitemia in the delayed fractional dose group), as per an article published in the Journal of Infectious Diseases.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top